From the Journals

Quicker fertility rebound in young women with breast cancer


 

Higher pregnancy rates

Almost 18% of women in the experimental arm reported trying to conceive, and 9.6% of them did so. About 10% of women in the cyclophosphamide arm tried to conceive, and 2.7% did so (P = .03).

The median interval between randomization and pregnancy was 42 months.

For all of the women who became pregnant, endocrine therapy was interrupted. “Women who temporarily interrupt endocrine therapy due to pregnancy should be reminded to resume endocrine therapy following attempted or successful pregnancy,” the investigators wrote.

The patients were taking tamoxifen at least 5 years after receiving chemotherapy, most often as monotherapy. About 5% of the patients underwent up-front ovarian suppression with an aromatase inhibitor, which is a current standard option.

The study was supported by the National Natural Science Foundation of China and other organizations. The investigators and Dr. Partridge disclosed no relevant financial relationships. Dr. Lambertini has consulted for and/or has received speakers fees from Roche, AstraZeneca, Lilly, Novartis, and other companies.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Breast MRI less accurate in predicting nodal status after neoadjuvant therapy in invasive lobular carcinoma
Breast Cancer ICYMI
Link between reproductive factors and breast cancer incidence
Breast Cancer ICYMI
Risk of 5-year local recurrence declines with event-free years in newly diagnosed breast cancer
Breast Cancer ICYMI
HER2+ BC: Recurrence risk remains even after achieving pCR with neoadjuvant pertuzumab+trastuzumab
Breast Cancer ICYMI
Clinical Edge Journal Scan Commentary: Breast Cancer April 2021
Breast Cancer ICYMI
Treating metastatic TNBC: Where are we now?
Breast Cancer ICYMI
Cancer screening stopped by pandemic: Repercussions to come?
Breast Cancer ICYMI
Steroid-refractory pneumonitis from ICIs: Experience at major centers
Breast Cancer ICYMI
Rankings of most common cancers to shift over next 20 years
Breast Cancer ICYMI
Personalized cancer vaccine shows early promise across tumor types
Breast Cancer ICYMI